Why one size no longer fits all in cancer treatment

Two people are diagnosed with the same type of cancer. They are of similar age, have similar symptoms, and are treated at the same hospital. Yet, one responds remarkably well to treatment while the other experiences little benefit.

Why does this happen?

For decades, cancer treatment largely followed a “one-size-fits-all” approach. Patients with the same type and stage of cancer were often offered similar treatment plans. While this strategy helped millions, it also highlighted an uncomfortable truth: cancer is far more complex than we once believed.

Today, advances in molecular medicine and genomics are transforming our understanding of cancer. We are entering an era where treatment is increasingly tailored not just to the cancer’s location, but to its unique biological signature.

Cancer Is a Disease of the Genes

Cancer develops when changes, or mutations, occur in our DNA, disrupting the normal mechanisms that regulate cell growth and repair. However, not all cancers carry the same mutations.

A lung cancer in one person may be driven by a completely different molecular pathway than lung cancer in another. Similarly, two breast cancers that appear identical under the microscope may behave very differently because of distinct genetic alterations.

Understanding these differences has become the foundation of precision oncology.

What Is Precision Oncology?

Precision oncology refers to the practice of using information about the genetic and molecular characteristics of a patient’s tumour to guide diagnosis, prognosis, and treatment decisions.

Instead of asking only, “Where did the cancer start?” physicians increasingly ask:

• What genetic alterations are driving this cancer?
• Are there targeted therapies available?
• Will immunotherapy be effective?
• Is this patient likely to benefit from a particular treatment?
• Are there clinical trials that may offer additional options?

These questions can help identify therapies that are more effective and potentially less toxic.

The Rise of Molecular Testing

Modern molecular diagnostic technologies allow us to analyze hundreds of genes from a tumour sample.

Tests may identify alterations that can be targeted by specific drugs. In some cancers, these findings can dramatically alter treatment strategies.

Molecular testing is now becoming an integral component of care in several cancers, including:

• Lung cancer
• Breast cancer
• Ovarian cancer
• Colorectal cancer
• Melanoma
• Certain blood cancers

However, it is important to understand that not every patient will have an actionable mutation, and molecular testing should always be interpreted within the broader clinical context.

What Patients Need to Know

The rapid evolution of cancer science has created hope, but also confusion.

Patients are often overwhelmed by terms such as genomics, biomarkers, targeted therapy, and immunotherapy. It is important to remember that more testing does not automatically translate into better outcomes. The right test should be performed for the right patient at the right time.

Conversations with qualified oncology teams remain essential.

Questions patients may consider asking include:

• Is molecular testing appropriate for my cancer?
• How could the results influence treatment decisions?
• What are the benefits and limitations?
• Are there additional treatment options or clinical trials based on the findings?

Being informed empowers patients to participate actively in their care.

Prevention Still Matters

As exciting as precision medicine may be, it does not replace the fundamentals of cancer prevention.

A significant proportion of cancers can be prevented through lifestyle choices and public health measures, including:

• Avoiding tobacco use.
• Maintaining a healthy body weight.
• Engaging in regular physical activity.
• Limiting alcohol consumption.
• Receiving recommended vaccinations.
• Participating in age-appropriate screening programmes.
• Seeking timely medical evaluation for persistent symptoms.

The future of cancer care lies not only in treating disease more intelligently but also in preventing it whenever possible.

Looking Ahead

We stand at a remarkable moment in medicine.

The convergence of molecular biology, genomics, artificial intelligence, and data science is reshaping the way we think about cancer. The goal is no longer simply to treat cancer; it is to understand each patient’s disease more deeply and make more informed decisions.

Precision oncology is not a promise of perfect outcomes. Cancer remains a formidable challenge. Yet, it offers something profoundly important: the possibility of delivering the right treatment to the right patient at the right time.

As we decode the biology of cancer, we move closer to a future where treatment is increasingly personalized, prevention is prioritized, and patients are empowered through knowledge.

Because when it comes to cancer, one size no longer fits all.

Disclaimer: This article is intended for educational and informational purposes only and should not be considered medical advice. Readers are advised to consult their healthcare professionals regarding individual medical concerns.

END OF ARTICLE